ArticleScientific reports2022
Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson's disease.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Cognitive function in different motor subtypes of Parkinson's disease: A systematic review and multilevel meta-analysis.Cognitive, affective & behavioral neuroscience · 2026Pooled it
- Pooled it
- Efficacy and Safety of Photobiomodulation Therapy for Motor Symptoms in Parkinson's Disease: A Systematic Review and Meta-Analysis.Brain sciences · 2026Review
- Associations of DTI-ALPS index and choroid plexus volume with clinical severity across the Parkinson's disease spectrum.NPJ Parkinson's disease · 2026Article
- Beyond the burden: Measuring the quality of life impact of Parkinson's on family members/partners using FROM-16.Journal of Parkinson's disease · 2026Article
- Wearable-sensor based walking and non-walking measures as progression markers in early to mid-stage Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Clinical, Genetic, and Imaging Characteristics of SCA27B: Insights from a Large Dutch Cohort.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Lipid Acyl Chain-Driven α-Synuclein Fibril Polymorphisms and Neuronal Pathologies.ACS chemical neuroscience · 2026Article
- Age at onset of Parkinson's disease modulates the sphingolipid-dopaminergic interplay in autonomic progression.NPJ Parkinson's disease · 2026Article
- Relationship between frailty and disease progression in Parkinson's disease: a 3-year longitudinal study.GeroScience · 2026Article
- The interplay between GBA1 status and age of onset on cognitive, motor and non-motor outcomes in Parkinson's disease: multicenter cross-sectional study.Journal of neurology · 2026Article
- Article
- Serum GDF-15 Levels Correlate With Motor and Nonmotor Symptom Domains and Overall Disease Severity in Patients With Parkinson's Disease.Parkinson's disease · 2026Article
- Long term improvement in quality of life in Parkinson's disease after deep brain stimulation of the subthalamic nucleus: an observational cohort.Clinical parkinsonism & related disorders · 2026Article
- Factors associated with self- perceived speech impairment inFrontiers in aging neuroscience · 2026Article
- Oxidative Stress-Related Serum Extracellular Vesicle miRNAs Indicate Symptom Severity and Cognitive Decline in Parkinson's Disease.Journal of neurochemistry · 2026Article
- Targeting Cdc42 improves motor phenotype in Parkinson's disease mice and reveals age-dependent susceptibility to α-synuclein.iScience · 2025Article
- The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases.Biology · 2025Review
- 'Pathology is disease' Parkinson's mythology: The 'brain-first-body-first' case study.Journal of Parkinson's disease · 2025Article
- Spontaneous eye blink-based machine learning for tracking clinical fluctuations in Parkinson's disease.NPJ Parkinson's disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is typically considered an age-related disease, but the age at disease onset can vary by decades between patients. Aging and aging-associated diseases can affect the movement system independently of PD, and advanced age has previously been proposed to be associated with a more severe PD phenotype with accelerated progression. In this work, we investigated how interactions between PD progression and aging affect a wide range of outcomes related to PD motor and nonmotor symptoms as well as Health Related Quality of Life (HRQoL) and treatment characteristics. This population-based cohort study is based on 1436 PD patients from southern Sweden followed longitudinally for up to approximately 7.5 years from enrollment (3470 visits covering 2285 patient years, average follow-up time 1.7 years). Higher age at onset was generally associated with faster progression of motor symptoms, with a notable exception of dyskinesia and other levodopa-associated motor fluctuations that had less severe trajectories for patients with higher age at onset. Mixed results were observed for emergence of non-motor symptoms, while higher age at onset was generally associated with worse HRQoL trajectories. Accounting for these identified age-associated differences in disease progression could positively impact patient management and drug development efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.